C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis
Open Access
- 19 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 26 (12) , 3980-3986
Abstract
Background. No previous randomized controlled studies have been reported examining de novo , once every 4 weeks (Q4W) administration of erythropoiesis-stimulating agents in chronic kidney disease (CKD) patients. We report results from a randomized multinational study that compared continuous erythropoietin receptor activator (C.E.R.A.) Q4W with darbepoetin alfa once weekly (QW) or every 2 weeks (Q2W) for the correction of anaemia in non-dialysis CKD patients. Methods. Patients were randomized (1:1) to receive either 1.2 μg/kg C.E.R.A. Q4W or darbepoetin alfa QW/Q2W during a 20-week correction period and an 8-week evaluation period. Two primary end points were assessed: the haemoglobin (Hb) response rate and the change in average Hb concentration between baseline and evaluation. Results. The Hb response rate for C.E.R.A. was 94.1%, significantly higher than the protocol-specified 60% response rate [95% confidence interval (CI): 89.1, 97.3; P < 0.0001] and comparable with darbepoetin alfa (93.5%; 95% CI: 88.4, 96.8; P < 0.0001). C.E.R.A. Q4W was non-inferior to darbepoetin alfa QW/Q2W, with similar mean Hb changes from baseline of 1.62 g/dL and 1.66 g/dL, respectively. Patients receiving C.E.R.A. showed a steady rise in Hb, with fewer patients above the target range during the first 8 weeks compared with darbepoetin alfa [39 patients (25.8%) versus 72 patients (47.7%); P < 0.0001]. Adverse event rates were comparable between the treatment groups. Conclusion. C.E.R.A. Q4W successfully corrects anaemia and maintains stable Hb levels within the recommended target range in non-dialysis CKD patients.Keywords
This publication has 14 references indexed in Scilit:
- Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trialNephrology Dialysis Transplantation, 2010
- C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension studyHemodialysis International, 2010
- C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on DialysisClinical Journal of the American Society of Nephrology, 2008
- Comparative Erythropoietin Receptor Binding Kinetics of C.E.R.A. and Epoetin-β Determined by Surface Plasmon Resonance and Competition Binding AssayPharmacology, 2007
- Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times WeeklyClinical Journal of the American Society of Nephrology, 2007
- Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfaCurrent Medical Research and Opinion, 2007
- Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2006
- Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfaCurrent Medical Research and Opinion, 2006
- The prevalence of anemia in patients with chronic kidney diseaseCurrent Medical Research and Opinion, 2004
- Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal DiseaseAnnals of Internal Medicine, 1989